Amgen Inc. (NASDAQ:AMGN) Shares Bought by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd raised its stake in Amgen Inc. (NASDAQ:AMGN) by 15.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 31,657 shares of the medical research company’s stock after buying an additional 4,161 shares during the quarter. Harvest Fund Management Co. Ltd’s holdings in Amgen were worth $8,199,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Vinva Investment Management Ltd lifted its position in Amgen by 22.7% in the fourth quarter. Vinva Investment Management Ltd now owns 26,522 shares of the medical research company’s stock valued at $6,877,000 after buying an additional 4,909 shares during the last quarter. Stokes Family Office LLC lifted its position in shares of Amgen by 117.6% during the fourth quarter. Stokes Family Office LLC now owns 4,104 shares of the medical research company’s stock worth $1,070,000 after purchasing an additional 2,218 shares in the last quarter. North Forty Two & Co. acquired a new stake in shares of Amgen during the fourth quarter worth about $631,000. VSM Wealth Advisory LLC acquired a new stake in shares of Amgen during the fourth quarter worth about $78,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new stake in shares of Amgen during the fourth quarter worth about $219,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In related news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the transaction, the executive vice president now directly owns 44,186 shares in the company, valued at $13,025,590.94. This trade represents a 16.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 in the last three months. Insiders own 0.69% of the company’s stock.

Amgen Stock Performance

Shares of AMGN opened at $318.65 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The firm has a market cap of $171.18 billion, a PE ratio of 42.21, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company’s 50 day simple moving average is $294.12 and its 200-day simple moving average is $298.91. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, equities analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 2.99%. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

Analysts Set New Price Targets

Several analysts have recently issued reports on AMGN shares. Bank of America increased their price target on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Leerink Partners reduced their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $310.00 target price on shares of Amgen in a report on Thursday, January 2nd. Finally, StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus price target of $314.04.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.